CLAIMS

1. A pharmaceutical composition that is formulated for topical application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is from 11:1 to 16:1.

2. The composition according to claim 1 for use as a medicament for treating and/or inhibiting the development or progression of cervical cancers and benign proliferative disorders of the cervix.

3. The composition according to claim 1 wherein lopinavir and ritonavir are included in a weight ratio of about 12:1.

4. The composition according to claim 1 wherein the composition is formulated as an ointment, gel, paste, cream, lotion, ovule, soft capsule, suppository, pessary, or any combination thereof.

5. The composition according to claim 1 wherein the pharmaceutically acceptable vehicle is an ointment.

6. The composition according to claim 5 wherein the composition is an anhydrous composition for topical application comprising:

(a) Lopinavir and ritonavir in a weight ratio from 11:1 to 16:1; and

(b) a hydrophilic muco-adhesive agent;

wherein upon topical administration of the anhydrous composition to a site of application the anhydrous composition transforms into a muco-adhesive composition.

7. The composition according to claim 6 wherein the muco-adhesive agent is hydroxypropylmethylcellulose.

8. The composition according to claim 6 comprising ritonavir, lopinavir, hydroxypropylmethylcellulose, oleic acid, stearic acid; and butylated hydroxytoluene.

9. The composition according to claim 5 wherein the composition comprises:

(a) an unsaturated free fatty acid;

(b) a stiffening agent; and

(c) lopinavir and ritonavir in a weight ratio from 11:1 to 16:1;

wherein the unsaturated free fatty acid is present at a level of at least 20% by weight of the total pharmaceutical composition weight and wherein the pharmaceutical composition is a semi-solid at room temperature.

10. Use of a therapeutically effective amount of a pharmaceutical composition according to claim 1, in the manufacture of a medicament for treating and/or inhibiting the development or progression of cervical cancers and benign proliferative disorders of the cervix in a subject in need of such treatment or inhibition, wherein the medicament is to be administered to said subject.

11. The use according to claim 10 wherein the cancer or disorder is caused or induced by a human papilloma virus (HPV).

12. Use of a therapeutically effective dose of a pharmaceutical composition according to claim 1, in the manufacture of a medicament for treating a patient having an HPV related dysplasia of the cervix, wherein the medicament is to be administered intravaginally to said patient.

13. The use of claim 12, wherein the pharmaceutical composition reduces the severity of the HPV related dysplasia.

14. The use of claim 13, wherein the severity of the HPV related dysplasia is reduced from CIN3 to CIN2, from CIN3 to CIN1, from CIN3 to HPV negative, from CIN2 to CIN1, from CIN2 to HPV negative, or from CIN1 to HPV negative.

15. The use of claim 11, wherein the composition induces apoptosis of HPV infected cells.

16. The use of claim 10, wherein the patient has a cervical cytology of high grade squamous intraepithelial lesion (HSIL), atypical squamous cells of undetermined significance (ASCUS), or low grade squamous intraepithelial lesion (LSIL).

17. The use of claim 16, wherein the composition reduces the cervical cytology from HSIL to a normal cytology, from HSIL to ACSUS, from HSIL to LSIL, from ACSUS to a normal cytology, or from LSIL to a normal cytology.

18. Use of an effective amount of a pharmaceutical composition according to claim 1, in the manufacture of a medicament for treating a Human Papilloma Virus (HPV) infection with or without attendant abnormal pathology.